Free shipping on all orders over $ 500

Torcetrapib

Cat. No. M1829

Torcetrapib Structure

Synonym: CP-529414

Size Price Availability Quantity
10mg USD 125 In stock
50mg USD 430 In stock
Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

Torcetrapib (CP-529414) is an inhibitor of cholesteryl ester transfer protein (CETP), it may reduce atherosclerotic vascular disease by increasing levels of high-density lipoprotein (HDL) cholesterol. In vivo endothelial mediated vasodilation was assessed using ultrasound imaging of acetylcholine-induced changes in rabbit central ear artery diameter. Torcetrapib, in addition to producing hypertension and baseline vasoconstriction, markedly inhibited acetylcholine-induced vasodilation. A structurally distinct CETP inhibitor, JNJ-28545595, did not affect endothelial function despite producing similar degrees of CETP inhibition and high-density lipoprotein elevation. Nitroprusside normalized torcetrapib's basal vasoconstriction and elicited dose-dependent vasodilation of norepinephrine preconstricted arteries in torcetrapib-treated animals, indicating torcetrapib did not impair smooth muscle function.

Protocol
Cell Experiment
Cell lines human adrenal carcinoma H295R cells
Preparation method To test our hypothesis that torcetrapib acts directly on the adrenal gland to increase adrenal steroid production and consequently causes electrolyte imbalance in the ILLUMINATE trial, human adrenal carcinoma H295R cells were incubated with torcetrapib for 24 and 48 h. Aldosterone and cortisol concentrations in the media were monitored by RIA and LC-MS-MS, respectively. Angiotensin II was used as a positive control. As shown in Fig. 1A, torcetrapib dose-dependently increased aldosterone release from H295R cells after either 24 or 48 h of treatment with an EC50 of approximately 80 nM.
Concentrations 10, 30, 100, 300, 1000 and 3000 n M
Incubation time 24 and 48 h
Animal Experiment
Animal models Male New Zealand White rabbits
Formulation 0.2% cholesterol, 10% coconut oil, and 1.2% ethyl lactate
Dosages 0.15, 0.3, and 0.6% (w/w) 1 week ∼90 mg/kg/day
Administration orally
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 600.47
Formula C26H25F9N2O4
CAS Number 262352-17-0
Purity >99%
Solubility DMSO ≥5 mg/mL
Storage at -20°C
References

Relationship between atorvastatin dose and the harm caused by torcetrapib.
Barter et al. J Lipid Res. 2012 Sep 2. PMID: 22941786.

On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Johns et al. Drugs. 2012 Mar 5;72(4):491-507. PMID: 22356288.

Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition.
Hu X, et al. Endocrinology. 2009 May;150(5):2211-9. PMID: 19164467.

Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits.
Morehouse LA, et al. J Lipid Res. 2007 Jun;48(6):1263-72. PMID: 17325387.

Related CETP Products
Dalcetrapib

Dalcetrapib (JTT-705) is a rhCETP inhibitor with IC50 of 0.2 μM that increases the plasma HDL cholesterol.

Evacetrapib

Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP which inhibited human recombinant CETP protein (5.5 nM IC(50)) and CETP activity in human plasma (36 nM IC(50)) in vitro.

Anacetrapib

Anacetrapib is an orally active and potent inhibitor of CETP with IC50 of 7.9 nM and 11.8 nM for rhCETP and mutant CETP(C13S) respectively.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Torcetrapib, CP-529414 supplier, CETP, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.